Homoharringtonine Plus Androgen Deprivation Therapy in the Neoadjuvant Treatment of Prostate Cancer: A Single-Arm Clinical Study

This study tests whether adding a drug called homoharringtonine (a plant-derived cancer medicine) to standard hormone-blocking therapy (androgen deprivation therapy) before prostate cancer surgery or other definitive treatment can shrink the tumor more effectively. **You may be eligible if...** - You are 18 to 85 years old - You have confirmed prostate cancer (high-risk localized, lymph node-involved, or metastatic) - You are in reasonably good physical health (ECOG 0–1) - Your organ function meets the study's thresholds **You may NOT be eligible if...** - You have had prior treatment for prostate cancer with certain therapies - You have significant other cancers or serious health conditions - Your blood counts or organ function do not meet the required levels Talk to your doctor to see if this trial is right for you.